Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Diabetic Foot Infections

  • Author: Michael Stuart Bronze, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
 
Updated: Feb 23, 2016
 

Practice Essentials

Compromise of the blood supply from microvascular disease, often in association with lack of sensation because of neuropathy, predisposes persons with diabetes mellitus to foot infections. These infections span the spectrum from simple, superficial cellulitis to chronic osteomyelitis.

The radiograph below demonstrates a foot lesion in a patient with diabetes.

Chronic diabetic ulceration with underlying osteom Chronic diabetic ulceration with underlying osteomyelitis. Plain film radiograph exhibiting cortical disruption at the medial aspect of the first MTP joint.

Signs and symptoms

Diabetic foot infections typically take one of the following forms:

  • Cellulitis
  • Deep-skin and soft-tissue infections
  • Acute osteomyelitis
  • Chronic osteomyelitis

Cellulitis

  • Tender, erythematous, nonraised skin lesions are present, sometimes with lymphangitis
  • Lymphangitis suggests group A streptococcal infection
  • Bullae are typical of Staphylococcus aureus infection, but occasionally occur with group A streptococci

· No ulcer or wound exudate is present

Deep-skin and soft-tissue infections

  • The patient may be acutely ill, with painful induration of the soft tissues in the extremity
  • Wound discharge is usually not present
  • In mixed infections that may involve anaerobes, crepitation may be noted over the afflicted area
  • Extreme pain and tenderness may indicate compartment syndrome or clostridial infection (ie, gas gangrene)
  • The tissues are not tense, and bullae may be present
  • Discharge, if present, is often foul

Acute osteomyelitis

  • Unless peripheral neuropathy is present, the patient has pain at the site of the involved bone
  • Usually, fever and regional adenopathy are absent

Chronic osteomyelitis

  • The patient's temperature is usually less than 102°F
  • Discharge is commonly foul
  • No lymphangitis is observed
  • Pain may or may not be present, depending on the degree of peripheral neuropathy
  • Deep, penetrating ulcers and deep sinus tracts (diagnostic of chronic osteomyelitis) are usually located between the toes or on the plantar surface of the foot
  • The medial malleoli, shins, or heels are not usually sites of involvement

See Clinical Presentation for more detail.

Diagnosis

Cellulitis

  • The WBC and ESR are slightly or moderately elevated, but these elevations are not diagnostic
  • Blood culture results are usually negative; if positive, they usually indicate the presence of group A or group B streptococci

Cultures of skin via aspiration or biopsy are generally unrewarding; aspiration of a sample from the leading edge of the erythematous border has a low yield (likely < 5%) but may be used if the likely organism must be identified on initial presentation

Skin and soft-tissue infections

  • The WBC and ESR are mildly or moderately elevated
  • If bullae are present, Gram stain and culture results from aspirated exudate from a bullous lesion may help identify the pathogen
  • Blood culture results may be positive
  • In suspected deep soft-tissue infection, plain radiography, CT, or MRI may be performed to evaluate for compartment syndrome or for gas or a foreign body in the deep tissues [1] ; excessive gas signifies a mixed aerobic-anaerobic infection, in contrast to gas gangrene (clostridial myonecrosis)
  • Gram stains and/or cultures of samples aspirated from deep-skin and soft-tissue infections may be used to identify the organism

Acute osteomyelitis

  • The WBC usually reveals leukocytosis, and the ESR is moderately or highly elevated [2]
  • Blood culture results are usually negative; when positive, the findings most frequently indicate the presence of S aureus
  • For affected long bones, plain radiographic findings generally become abnormal after 10-14 days; soft-tissue swelling and periosteal elevation are the earliest signs
  • Bone scans are preferred to gallium or indium scans; bone-scan findings are positive within 24 hours
  • Bone biopsy is not necessary

Chronic osteomyelitis

  • The WBC is often within the reference range; the ESR is usually very highly elevated and may exceed 100 mm/hr [2] ; the platelet count is also often elevated
  • Blood culture results are usually negative
  • Plain radiographic findings are invariably abnormal
  • Bone scans are usually unnecessary unless diagnostic confusion exists with another disorder (eg, bone tumor); an MRI scan would also be helpful in such a situation
  • Bone biopsy performed under aseptic conditions in the operating room is the preferred way to identify the causative pathogen
  • Important pathogens include Bacteroides fragilis, E coli, Proteus mirabilis, and Klebsiella pneumoniae; Pseudomonas aeruginosa is usually not the causative organism

See Workup for more detail.

Management

Treatment of diabetic foot infections varies by type, as follows:

  • Cellulitis – Most responsive to antibiotics
  • Deep skin and soft-tissue infections – Usually curable, but additional debridement is usually indicated
  • Acute osteomyelitis – Infecting microorganisms and the likelihood of successful treatment with antimicrobial therapy are essentially the same as in patients without diabetes
  • Chronic osteomyelitis – Surgical debridement is essential, in addition to antibiotics; amputation may be necessary

See Treatment and Medication for more detail.

Next

Background

Foot infections are the most common problems in persons with diabetes. These individuals are predisposed to foot infections because of a compromised vascular supply secondary to diabetes. Local trauma and/or pressure (often in association with lack of sensation because of neuropathy), in addition to microvascular disease, may result in various diabetic foot infections that run the spectrum from simple, superficial cellulitis to chronic osteomyelitis.

The radiograph below demonstrates a foot lesion in a patient with diabetes.

Chronic diabetic ulceration with underlying osteom Chronic diabetic ulceration with underlying osteomyelitis. Plain film radiograph exhibiting cortical disruption at the medial aspect of the first MTP joint.

Infections in patients with diabetes are difficult to treat because these individuals have impaired microvascular circulation, which limits the access of phagocytic cells to the infected area and results in a poor concentration of antibiotics in the infected tissues. In addition, diabetic individuals can not only have a combined infection involving bone and soft tissue called fetid foot, a severe and extensive, chronic soft-tissue and bone infection that causes a foul exudate, but they may also have peripheral vascular disease that involves the large vessels, as well as microvascular and capillary disease that results in peripheral vascular disease with gangrene.[3, 4, 5, 6, 7]

Except for chronic osteomyelitis, infections in patients with diabetes are caused by the same microorganisms that can infect the extremities of persons without diabetes. Gas gangrene is conspicuous because of its low incidence in patients with diabetes, but deep-skin and soft-tissue infections, which are due to gas-producing organisms, frequently occur in patients with these infections.

In general, foot infections in persons with diabetes become more severe and take longer to cure than do equivalent infections in persons without diabetes.

Staging in diabetic foot infections is applicable only in cases of chronic osteomyelitis that require surgery.

Go to Type 1 Diabetes Mellitus,Type 2 Diabetes Mellitus, and Diabetic Ulcers to see more complete information on these topics.

Previous
Next

Pathophysiology

In chronic osteomyelitis, a sequestrum and involucrum form; these represent islands of infected bone. Bone fragments that are isolated have no blood supply.

Bacteremia may accompany cellulitis, skin or soft-tissue infections, and/or acute osteomyelitis, but this is not a complication per se. If chronic osteomyelitis is left untreated for years, it may lead to complications such as amyloidosis or squamous cell carcinoma at the site of drainage through the skin. Bacteremia and septic shock rarely, if ever, occur as a result of chronic osteomyelitis.

Previous
Next

Etiology

Diabetes mellitus is a disorder that primarily affects the microvascular circulation. In the extremities, microvascular disease due to "sugar-coated capillaries" limits the blood supply to the superficial and deep structures. Pressure due to ill-fitting shoes or trauma further compromises the local blood supply at the microvascular level, predisposing the patient to infection, which may involve the skin, soft tissues, bone, or all of these combined.

Diabetes also accelerates macrovascular disease, which is evident clinically as accelerating atherosclerosis and/or peripheral vascular disease. Most diabetic foot infections occur in the setting of good dorsalis pedis pulses; this finding indicates that the primary problem in diabetic foot infections is microvascular compromise.

Impaired microvascular circulation hinders white blood cell migration into the area of infection and limits the ability of antibiotics to reach the site of infection in an effective concentration. Diabetic neuropathy may be encountered in conjunction with vasculopathy. This may allow for incidental trauma that goes unrecognized (eg, blistering, penetrating foreign body). Go to Diabetic Neuropathy for more complete information on this topic.

Microbial characteristics

The microbiologic features of diabetic foot infections vary according to the tissue infected. In patients with diabetes, superficial skin infections, such as cellulitis, are caused by the same organisms as those in healthy hosts, namely group A streptococci and Staphylococcus aureus. In unusual epidemiologic circumstances, however, organisms such as Pasteurella multocida (eg, from dog or cat bites or scratches) may be noted and should always be considered. Group B streptococcal cellulitis is uncommon in healthy hosts but not uncommon in patients with diabetes. In diabetic individuals, group B streptococci may cause urinary tract infections and catheter-associated bacteriuria in addition to cellulitis, skin and/or soft-tissue infections, and chronic osteomyelitis. Such infections may be complicated by bacteremia.

Furthermore, as previously mentioned, deep soft-tissue infections in diabetic persons can be associated with gas-producing, gram-negative bacilli. Clinically, these infections appear as necrotizing fasciitis, compartment syndrome, or myositis. Gas gangrene is uncommon in persons with diabetes.

Acute osteomyelitis usually occurs as a result of foot trauma in an individual with diabetes. The distribution of organisms is the same as that in an individual without diabetes who has acute osteomyelitis. In chronic osteomyelitis, however, the pathogens include group A and group B streptococci, aerobic gram-negative bacilli, and Bacteroides fragilis.

Other pathogens implicated in chronic osteomyelitis in patients with diabetes include B fragilis, Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.

Pseudomonas aeruginosa is generally not a pathogen in chronic osteomyelitis in these individuals. Although P aeruginosa is frequently cultured from samples obtained from a draining sinus tract or deep penetrating ulcers in patients with diabetes, these organisms are superficial colonizers and are generally not the cause of the bone infection.

Because Pseudomonas organisms are water-borne, superficial ulcers may be contaminated by bacteria in wet socks or dressings. To the authors' knowledge, however, no well-documented cases of biopsy-proven P aeruginosa infection have been reported in patients with chronic osteomyelitis.

Fetid foot represents a combined deep-skin and soft-tissue infection caused by pathogens involved in chronic osteomyelitis.

Previous
Next

Epidemiology

Globally, diabetic foot infections are the most common skeletal and soft-tissue infections in patients with diabetes. The incidence of diabetic foot infections is similar to that of diabetes in various ethnic groups and most frequently affect elderly patients. There are no significant differences between the sexes.

Mortality is not common, except in unusual circumstances. The mortality risk is highest in patients with chronic osteomyelitis and in those with acute necrotizing soft-tissue infections.

Previous
Next

Prognosis

The prognosis for cases of cellulitis, skin and/or soft-tissue infections, and acute osteomyelitis depends on the adequacy of antimicrobial therapy and surgical debridement. For cases of chronic osteomyelitis, the prognosis is directly related to the vascular supply in the affected limb and the adequacy of surgical debridement.

In a German study, nearly 250 patients with diabetic foot ulcers were evaluated and followed over time. Major adverse risk factors for long-term limb salvage included the presence of significant peripheral artery disease and renal insufficiency.[8]

Previous
Next

Patient Education

Patients with diabetes must be careful to avoid foot trauma and to properly care for their feet to minimize the possibility of infection. In addition, they must understand that chronic osteomyelitis cannot be cured with antibiotics alone and that adequate surgical debridement is necessary.

Patients who are unwilling to undergo the surgical procedure must understand the long-term complications of chronic osteomyelitis. They should be advised that if the infection is not adequately treated with sufficient surgical debridement and/or amputation, systemic complications, including bacteremia and/or systemic infection, amyloidosis, and squamous cell carcinoma at the affected site, may occur over time.

Long-term suppressive therapy may decrease the incidence of septic complications, but it does not affect the long-term complications, which may include amyloidosis or squamous cell carcinoma at the drainage site.

For patient education information, see the Diabetes Center, as well as Diabetic Foot Care.

Previous
 
 
Contributor Information and Disclosures
Author

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, Oklahoma State Medical Association, Southern Society for Clinical Investigation, Association of Professors of Medicine, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Coauthor(s)

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Richard B Brown, MD, FACP Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine

Richard B Brown, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, Massachusetts Medical Society

Disclosure: Nothing to disclose.

Chief Editor

Romesh Khardori, MD, PhD, FACP Professor of Endocrinology, Director of Training Program, Division of Endocrinology, Diabetes and Metabolism, Strelitz Diabetes and Endocrine Disorders Institute, Department of Internal Medicine, Eastern Virginia Medical School

Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, Endocrine Society

Disclosure: Nothing to disclose.

Additional Contributors

Charles S Levy, MD Associate Professor, Department of Medicine, Section of Infectious Disease, George Washington University School of Medicine

Charles S Levy, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America, Medical Society of the District of Columbia

Disclosure: Nothing to disclose.

References
  1. Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. Br J Radiol. 2007 Nov. 80(959):939-48. [Medline]. [Full Text].

  2. Malabu UH, Al-Rubeaan KA, Al-Derewish M. Diabetic foot osteomyelitis: usefulness of erythrocyte sedimentation rate in its diagnosis. West Afr J Med. 2007 Apr-Jun. 26(2):113-6. [Medline].

  3. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005 Nov 12. 366(9498):1695-703. [Medline].

  4. Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. 2007 Aug. 60(2):370-6. [Medline]. [Full Text].

  5. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005 Feb. 55(2):240-5. [Medline]. [Full Text].

  6. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. 2007 Oct. 60(4):819-23. [Medline]. [Full Text].

  7. Wang S, Cunha BA, Hamid NS, Amato BM, Feuerman M, Malone B. Metronidazole single versus multiple daily dosing in serious intraabdominal/pelvic and diabetic foot infections. J Chemother. 2007 Aug. 19(4):410-6. [Medline].

  8. Morbach S, Furchert H, Gröblinghoff U, Hoffmeier H, Kersten K, Klauke GT, et al. Long-Term Prognosis of Diabetic Foot Patients and Their Limbs: Amputation and death over the course of a decade. Diabetes Care. 2012 Jul 18. [Medline].

  9. [Guideline] Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016 Feb. 63 (2 Suppl):3S-21S. [Medline].

  10. Tucker ME. New guidelines stress need for diabetic foot ulcer offloading. Medscape Medical News. Available at http://www.medscape.com/viewarticle/837220. Accessed: December 26, 2014.

  11. Snyder RJ, Frykberg RG, Rogers LC, Applewhite AJ, Bell D, Bohn G. The management of diabetic foot ulcers through optimal off-loading: building consensus guidelines and practical recommendations to improve outcomes. J Am Podiatr Med Assoc. 2014 Nov. 104(6):555-67. [Medline].

  12. Rogers LC, Frykberg RG, Armstrong DG, et al. The Charcot foot in diabetes. Diabetes Care. 2011 Sep. 34(9):2123-9. [Medline].

  13. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012 Jun. 54(12):e132-73. [Medline].

  14. Tucker M. Short-Course Antibiotics Good in Diabetic Foot Osteomyelitis. Medscape Medical News. Available at http://www.medscape.com/viewarticle/835503. Accessed: November 27, 2014.

  15. Tone A, Nguyen S, Devemy F, Topolinski H, Valette M, Cazaubiel M, et al. Six- Versus Twelve-Week Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study. Diabetes Care. 2014 Nov 20. [Medline].

  16. US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox®) is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm. Accessed: July 27, 2011.

  17. Lázaro-Martínez J, Aragón-Sánchez J, García-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis. A randomized comparative trial. Diabetes Care. 2013 Oct 15. [Medline].

  18. Nainggolan L. Antibiotics First Choice for Diabetic Foot Osteomyelitis. Available at http://www.medscape.com/viewarticle/813142. Accessed: October 28, 2013.

 
Previous
Next
 
Chronic diabetic ulceration with underlying osteomyelitis. Plain film radiograph exhibiting cortical disruption at the medial aspect of the first MTP joint.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.